Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Last year, Thrive Global teamed up with OpenAI to create Thrive AI Health, an AI-powered health coach trained on the ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...